greeksoup/ stock research
Stock research / United States / CBIO / Planned sales

Crescent Biopharma, Inc. planned insider sales

In the last twelve months insiders at Crescent Biopharma, Inc. filed 4 Form 144 notices of planned sales, 16,003 shares worth $279,103 at the time of filing, from 2 sellers. The latest, filed 17 September 2026: Jonathan McNeill (officer), 4,415 shares worth $75,850, planned for around 18 September 2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.

FiledSellerRelationshipSharesValuePlanned saleSold, per Form 4BrokerHow acquiredFiling
17 September 2026Jonathan McNeillOfficer4,415$75,85018 September 20264,570 shares from 16 September 2026Morgan Stanley Smith Barney LLC Executive Financial ServicesRestricted Stock Unit VestingForm 144
17 September 2026Joshua T BrummOfficer, Director9,013$154,84318 September 20269,447 shares from 16 September 2026Morgan Stanley Smith Barney LLC Executive Financial ServicesRestricted Stock Unit VestingForm 144
16 September 2026Jonathan McNeillOfficer804$15,11516 September 2026None on Form 4 yetMorgan Stanley Smith Barney LLC Executive Financial ServicesRestricted Stock Unit VestingForm 144
16 September 2026Joshua T BrummOfficer, Director1,771$33,29516 September 2026None on Form 4 yetMorgan Stanley Smith Barney LLC Executive Financial ServicesRestricted Stock Unit VestingForm 144
A Form 144 is the notice an insider files with the SEC before selling restricted or control shares over the Rule 144 thresholds; it says what may be sold, not what was.
Read moreValue is the filer's own aggregate market value. Sold, per Form 4: the same seller's open-market sales on Form 4 from the notice's date to 90 days after, added up, as they appear on the insiders page; a holder who files no Form 4, such as some large holders, never shows one. What is a Form 144?